Best Practice & Research Clinical Haematology最新文献

Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025] “精确免疫调节：理解和利用细胞因子途径来治疗和预防免疫相关不良事件（irAEs）”的勘误表[最佳实践Res临床血血学38 2 2025]

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-07-18 DOI: 10.1016/j.beha.2025.101648

Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds

引用次数: 0

Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception 前体浆细胞疾病：分类、风险分层和早期阻断的新作用

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-07-09 DOI: 10.1016/j.beha.2025.101641

Tarek H. Mouhieddine , Irene M. Ghobrial , Omar Nadeem

引用次数: 0

Immune therapy of haematological cancers 血液学癌症的免疫治疗

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-04 DOI: 10.1016/j.beha.2025.101640

Bin Pan , Robert Peter Gale MD, PhD, DSc(hc), FACP, FRCP, FRCPI(hc), FRSM

引用次数: 0

Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs) 精确免疫调节：理解和利用细胞因子途径治疗和预防免疫相关不良事件（irAEs）

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 DOI: 10.1016/j.beha.2025.101625

Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds

{"title":"Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)","authors":"Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds","doi":"10.1016/j.beha.2025.101625","DOIUrl":"10.1016/j.beha.2025.101625","url":null,"abstract":"<div><div>The utilization of immune checkpoint inhibitors has fundamentally changed both the treatment landscape for a multitude of malignancies as well as our understanding of cancer biology. Despite profound advancements, the utilization of these drugs is often limited by the development of immune-related adverse events (irAEs), characterized by off-target toxicity to healthy tissue secondary to treatment. Currently, irAEs are often treated with high-dose corticosteroids, with additional immunosuppressive agents added for severe or refractory irAEs. Cytokine pathway inhibitors, particularly anti-TNFa and anti-IL-6R antibodies, are commonly used as second-line immunosuppression. The efficacy of blocking these pathways in treating irAEs, as well as their potential impact on anti-tumor response, will be discussed. Additionally, this review will also explore other cytokines implicated in irAE pathophysiology, including interleukin-17 (IL-17), interleukin-23 (IL-23), interleukin-4/13 (IL-4/IL-13) and interleukin-5 (IL-5) which play important roles in the inflammatory cascades underlying specific irAEs such as colitis, dermatitis, and eosinophilia-related toxicities.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101625"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in NK cell therapy for multiple myeloma NK细胞治疗多发性骨髓瘤的进展

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-28 DOI: 10.1016/j.beha.2025.101639

Najing Liu , Yujin Zeng , Ying Wang , Congyue Wang , Nuoxian Li , Jinge Xu

引用次数: 0

Adoptive cellular therapies in multiple myeloma 多发性骨髓瘤的过继细胞治疗

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-27 DOI: 10.1016/j.beha.2025.101638

David Kegyes , Bogdan Borlea , Marc Damian , Adrian Bogdan Tigu , Madalina Nistor , Diana Cenariu , Raluca Munteanu , Diana Gulei , Angela Dascalescu , Ion Antohe , Alina Tanase , Evangelos Terpos , Hermann Einsele , Ciprian Tomuleasa

{"title":"Adoptive cellular therapies in multiple myeloma","authors":"David Kegyes , Bogdan Borlea , Marc Damian , Adrian Bogdan Tigu , Madalina Nistor , Diana Cenariu , Raluca Munteanu , Diana Gulei , Angela Dascalescu , Ion Antohe , Alina Tanase , Evangelos Terpos , Hermann Einsele , Ciprian Tomuleasa","doi":"10.1016/j.beha.2025.101638","DOIUrl":"10.1016/j.beha.2025.101638","url":null,"abstract":"<div><div>Plasma cell myeloma (multiple myeloma) is a blood cancer characterized by the clonal proliferation of plasma cells in the bone marrow. Treatment strategies evolve year by year, new drugs getting Food and Drug Administration (FDA)-approved each year. Chimeric antigen receptor (CAR) therapies are an advanced form of immunotherapy that engineer T cells to recognize and destroy cancer cells. In recent years, adoptive cellular therapies have been successfully used to treat relapsed or refractory patients. Now, growing evidence supports their effectiveness when used earlier in treatment, even as an alternative to autologous hematopoietic stem cell transplantation. Ongoing research is expanding CAR therapy to solid tumors and enhancing safety and efficacy through innovative designs and combination strategies. In this paper, we aim to highlight the brief history and the latest advancements in CAR T-cell and NK-cell therapies for plasma cell myeloma.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 3","pages":"Article 101638"},"PeriodicalIF":2.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144203182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adoptive cellular therapies in non-Hodgkin lymphomas 非霍奇金淋巴瘤的过继细胞治疗

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-22 DOI: 10.1016/j.beha.2025.101637

David Kegyes , Bogdan Borlea , Marc Damian , Adrian Bogdan Tigu , Madalina Nistor , Diana Cenariu , Raluca Munteanu , Diana Gulei , Angela Dascalescu , Ion Antohe , Alina Tanase , Anca Colita , Nazar Shokun , Tetiana Skrypets , Hermann Einsele , Massimo Federico , Ciprian Tomuleasa

{"title":"Adoptive cellular therapies in non-Hodgkin lymphomas","authors":"David Kegyes , Bogdan Borlea , Marc Damian , Adrian Bogdan Tigu , Madalina Nistor , Diana Cenariu , Raluca Munteanu , Diana Gulei , Angela Dascalescu , Ion Antohe , Alina Tanase , Anca Colita , Nazar Shokun , Tetiana Skrypets , Hermann Einsele , Massimo Federico , Ciprian Tomuleasa","doi":"10.1016/j.beha.2025.101637","DOIUrl":"10.1016/j.beha.2025.101637","url":null,"abstract":"<div><div>Lymphomas are a group of malignant proliferations of B, T or NK-lymphoid cells at different stages of maturation. While they primarily occur in lymph nodes or lymphatic tissues, they can also involve bone marrow, blood, or other organs. Despite advances in treatment, many patients experience relapse, or develop refractory disease, prompting the development of new therapies. One of the most promising innovations is represented by chimeric antigen receptors (CAR) T-cell therapy, that works by genetically modifying a patient's T lymphocytes to better target and kill their cancer cells. Currently, all FDA-approved CAR T-cell therapies target CD19 (a surface protein expressed on B lymphocytes), however, ongoing research includes CAR-Ts that address novel targets or target multiple antigens. This study aims to provide a comprehensive overview on the clinical use and therapeutic efficacy of both approved and emerging CAR-Ts in the treatment of lymphoma.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 3","pages":"Article 101637"},"PeriodicalIF":2.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144189302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology 利用间充质干细胞和其他血液新细胞的治疗方案

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-21 DOI: 10.1016/j.beha.2025.101636

Leland Metheny MD (Associate Professor)

引用次数: 0

Immune reconstitution following allogeneic hematopoietic cell transplantation and CAR-T therapy: dynamics, determinants, and directions 同种异体造血细胞移植和CAR-T治疗后的免疫重建：动力学、决定因素和方向

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-16 DOI: 10.1016/j.beha.2025.101634

Weijia Fu , Jiahao Chen , Xiaoxia Hu

{"title":"Immune reconstitution following allogeneic hematopoietic cell transplantation and CAR-T therapy: dynamics, determinants, and directions","authors":"Weijia Fu , Jiahao Chen , Xiaoxia Hu","doi":"10.1016/j.beha.2025.101634","DOIUrl":"10.1016/j.beha.2025.101634","url":null,"abstract":"<div><div>Immune reconstitution (IR) is a dynamic and sequential process that occurs after allogeneic hematopoietic cell transplantation (allo-HCT) and cellular therapies, involving the gradual recovery of both innate and adaptive immune compartments. The success of IR is a critical determinant of clinical outcomes, including the risk of graft-versus-host disease and graft-versus-leukemia effects. In the context of allo-HCT, IR shaped by various factors, including transplantation modalities, conditioning regimens, therapeutic interventions, and post-transplant strategies. The kinetics and quality of IR following chimeric antigen receptor T-cell (CAR-T) therapy are also shaped by several factors, such as lymphodepleting chemotherapy, CAR construct design, and the patient's baseline immune status. In particular, B-cell–targeted CAR-T therapy frequently results in B-cell aplasia, hypogammaglobulinemia, and immune exhaustion, necessitating improved monitoring and post-treatment interventions. These immunologic effects highlight the need for improved post-treatment monitoring and supportive interventions to reduce infection risk and ensure sustained immune recovery. To better characterize IR across both allo-HCT and CAR-T settings, advanced immune profiling technologies, such as flow cytometry and single-cell RNA sequencing, are providing new insights into the dynamics of immune recovery. Here, we summarize current knowledge on IR kinetics and evaluate the impact of different transplant and CAR-T settings. We then discuss personalized strategies to optimize immune monitoring and therapeutic approaches for recipients of allo-HCT and CAR-T therapies.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101634"},"PeriodicalIF":2.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144106976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse 靶向BCMA CAR-T治疗复发/难治性多发性骨髓瘤抗原阴性复发的研究进展

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-05-15 DOI: 10.1016/j.beha.2025.101632

Lulu Kong , Kailin Xu , Wei Chen

{"title":"Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse","authors":"Lulu Kong , Kailin Xu , Wei Chen","doi":"10.1016/j.beha.2025.101632","DOIUrl":"10.1016/j.beha.2025.101632","url":null,"abstract":"<div><div>Chimeric antigen receptor T cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has emerged as a novel and effective modality for the treatment of relapsed or refractory multiple myeloma (RRMM), achieving remarkable therapeutic outcomes. However, relapse remains a major problem impeding the long-term efficacy of this therapy, with antigen-negative relapse being a particularly challenging issue. The mechanisms underlying BCMA antigen-negative relapse encompass a spectrum of phenomena, including diminished or lost tumor antigen expression, BCMA shedding, impaired antigen presentation, trogocytosis, antigen mutations, and alternative splicing. To overcome the problem of antigen-negative relapse in BCMA CAR-T therapy, a variety of strategies are being explored. These include dual/multi-specific CAR-T cell therapy, combination therapies with antibody-drug conjugates (ADCs) or bispecific T-cell engagers (BiTEs), integration with hematopoietic stem cell transplantation (HSCT), identification of novel targets, and the development of innovative cell therapies such as CAR-NK and CAR-M (CAR-Macrophage). Additionally, the optimization of CAR-T cells through gene editing technologies to enhance their durability and anti-tumor activity is a burgeoning area of research. In future, targeted BCMA CAR-T therapy is poised to place greater emphasis on individualization and precision medicine, combining multiple therapeutic approaches to reduce the incidence of relapse, thereby improving treatment efficacy and longevity.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101632"},"PeriodicalIF":2.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0